The 1.6mm laser fiber probe features patented NeuroBlate System cooling technology and is available in a single adjustable length.

Minnetonka, Minnesota-based Monteris won FDA 510(k) clearance to add the NB3 to its NeuroBlate system’s devices and accessories in December 2023 and started a limited market release in February.

“Surgeons participating in the initial launch phase used the probe across a comprehensive set of workflows, lesion types, sizes, locations, target depths and patient profiles,” the company said in a news release. “Lesion types include primary tumors, progressive metastatic lesions, radiation necrosis and epileptogenic foci in both adult and pediatric patients. Lesion sizes ablated during limited market release have ranged from less than 10mm in diameter to nearly 30mm in diameter and have included deep-seated targets and multiple trajectory procedures.”